PHARMACOVIGILANCE IN CLINICAL RESEARCH: PAST, PRESENT AND FUTURE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 4
Abstract
The growing clinical research after the product patents rights for the pharmaceutical industries as per the trade related aspects of intellectual property rights agreement and adverse drug reaction monitoring of the marketed drugs have raised many ethical and regulatory issues regarding the promotion of new drugs in Indian markets. It becomes vital to understand the history, growth and evolution of the regulatory aspects of drugs which are handled by multiple Ministries and Departments of the Government of India. Although amendment to Schedule Y, registration of Ethics committee, registration of Clinical Trials, Speeding up review process, Pharmacovigilance (PhV) programme for India and Inspection of clinical trial sites have been started by the various regulatory agencies. India’s growing partaking in multinational trials, this artifact explores potential areas of Indian pharmacovigilance, requiring reform and provides recommendations for building a robust safety reporting system. (1) Despite global focus on Development Safety Update Report, local regulators are not yet insistent on real-time update of a drug's cumulative safety profile. Issues like reporting requirements for generic trials, pregnancy reporting and lenient timeline for death/life-threatening events need attention. (2)
Authors and Affiliations
Chauhan Pratibha, Yadav Ashish, Kirodian Babita
Keywords
Related Articles
- EP ID EP337075
- DOI 10.22270/ijdra.v4i4.188
- Views 122
- Downloads 0
COMMON DEFICIENCIES RAISED BY VARIOUS REGULATORY AGENCIES
Timely Product registration is a challenge in today’s scenario. Regulatory agencies are keen in assessing CTD sections like redefining starting material of Drug substance manufacturing, Pharmaceutical development, impuri...
Regulation of Blood and Blood products in India, USA and EU
Blood and blood products are precious commodity which gives life to another person. Though we have immense discoveries and invention in science and technology, yet we cannot make blood hence, human blood has no substitut...
Integrating PLCM strategy in Pharmaceutical Emerging Market
All products and services must denote definite life cycles. The life cycle talks about the period from the product‘s first launch till it wind-up onto the market. Throughout this age noteworthy modifications are made in...
DRUG REGULATION IN INDIA: SWOT ANALYSIS
Drug regulation plays pivotal role in any country because the purpose of drug regulation is to promote and to protect public health by ensuring the safety, efficacy and quality of drugs. Drug regulation should cover all...
RISK DRIVERS OF FALSIFIED AND SUB-STANDARD MEDICINES IN EAST AFRICA: PERCEPTIONS AND PRACTICES OF PHARMACEUTICAL DRUG FACILITY OWNERS/EMPLOYEES
An interview survey was conducted among drug shop owners to investigate the access to and perception of counterfeit medication along transport corridors of East Africa spanning Kenya, Tanzania, Uganda and Democratic Repu...